To read the full story, subscribe or sign in.

ExonHit Partners With IDEC To Develop Antibody Therapeutics

Jan. 9, 2002

PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for April 21, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...